Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

17 Aug 2020

Abstract excerpt

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. The combination of cisplatin (CDDP) plus cetuximab (CX) is one of the standard first-line treatments in this disease. However, this therapeutic regimen is often associated with high toxicity and resistance, suggesting that new combinatorial strategies are needed to improve its therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33015030
DOI: 10.3389/fcell.2020.00732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of ResistancePMID 33015030Read ↗

Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection.Semantic proximity Read ↗

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.Semantic proximity Read ↗

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinomaSemantic proximity Read ↗

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.Semantic proximity Read ↗

KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Senataxin modulates resistance to cisplatin through an R-loop mediated mechanism in HPV-associated Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Triple action Pt( iv ) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistanceSemantic proximity Read ↗

The impact of<i>ERP29</i>on the progression of pharyngeal squamous cell carcinomaSemantic proximity Read ↗

Nanoformulated cell-penetrating survivin mutant and its dual actions.Semantic proximity Read ↗

A Head and Neck Cancer Spheroid Model for Phenotypic High-Content Screening of Chemoresistance.Semantic proximity Read ↗

Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck CancerSemantic proximity Read ↗

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.